Literature DB >> 9467175

The binding potential of commercial antibody conjugates with sera of various small terrestrial mammals.

A Pretorius1, M J Oelofsen, M S Smith, E van der Ryst.   

Abstract

Infectious diseases of wild animals are of increasing importance, both from an economic viewpoint and because several of these diseases are pathogenic to man. However, serosurveys to determine the circulation of infectious organisms in wildlife are complicated by the fact that antibodies to species-specific immunoglobulins are not available for use in serological assays such as enzyme-linked immunosorbent assays (ELISAs) or immunofluorescence assays. To determine the binding potential of four commercially available antibody conjugates with the sera of wild animals, sera from 27 species of small terrestrial mammals were allowed to react with alkaline phosphatase-labelled protein A, anti-rabbit IgG, anti-mouse IgG and anti-human IgG by by the use of an ELISA. It was found that sera from some species of the order Lagomorpha bound optimally to anti-rabbit IgG, while anti-mouse IgG could be used for most species of Rodentia. For all Carnivora, Insectivora, Macroscelidea, Hyracoidea and other Rodentia, staphylococcal protein A demonstrated optimal binding. None of the sera that was tested bound to anti-human IgG. These results demonstrate that commercial conjugates can be used in serological assays in which wild animal sera are used, and should be useful for future serosurveys to determine the circulation of infectious agents in small terrestrial mammals.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9467175

Source DB:  PubMed          Journal:  Onderstepoort J Vet Res        ISSN: 0030-2465            Impact factor:   1.792


  1 in total

1.  Generation and characterization of antibodies against Asian elephant (Elephas maximus) IgG, IgM, and IgA.

Authors:  Alan F Humphreys; Jie Tan; RongSheng Peng; Susan M Benton; Xiang Qin; Kim C Worley; Rose L Mikulski; Dar-Chone Chow; Timothy G Palzkill; Paul D Ling
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.